The short answer
Insulin resistance is not itself an FDA indication, but GLP-1s directly improve insulin sensitivity and are prescribed off-label or via weight-management criteria.
Ozempic specifically
Off-label for isolated insulin resistance; on-label once type 2 diabetes is diagnosed.
BMI & eligibility
Coverage for insulin resistance follows the obesity (BMI ≥30, or ≥27 with comorbidity) or diabetes pathway. Insulin resistance without elevated BMI or A1c is hard to get covered.
Check your BMI
BMI calculator
BMI 27-29.9 — eligible if comorbidity (T2D, hypertension, sleep apnea, PCOS).
BMI is one signal among several. Waist circumference, body composition, metabolic markers, and clinical history also matter — talk to a prescriber.
Insurance & coverage
No insurer covers a GLP-1 for "insulin resistance" as a standalone diagnosis. Document obesity or diabetes for the prior authorization, or use cash-pay/compounded routes.
Check if your plan covers itWe earn affiliate commissions from listed providers. See our editorial standards.
Other GLP-1s for insulin resistance
Ozempic for other conditions
Sources
Educational information, not medical advice. FDA-approval status reflects labeling as of 2026; off-label prescribing is legal and common but coverage varies.